GeoVax Labs (OTCMKTS:GOVX)

GeoVax Labs, Inc. (OTCBB: GOVX) is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using our novel DNA/MVA platform technology. Our platform supports production of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine.  Producing VLPs in the person being vaccinated mimics a natural infection,...

GeoVax Labs, Inc. (OTCBB: GOVX) is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using our novel DNA/MVA platform technology. Our platform supports production of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine.  Producing VLPs in the person being vaccinated mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent and control the target infection should it appear.

Our current development programs are focused on vaccines against hemorrhagic fever viruses such as Ebola, and against Human Immunodeficiency Virus (HIV).  We have also recently initiated a program to apply our MVA-VLP vector technology to cancer immunotherapy (immuno-oncology). We believe our technology and vaccine development expertise is well-suited for a wide variety of human diseases for which there is an unmet medical need, and we intend to pursue expansion of our product pipeline.